SCHEMBL4575348

SCHEMBL4575348

CC(C)(Oc1ccc(CCN(Cc2ccc(-c3noc(C4CC4)n3)cc2)c2noc(-c3ccccc3F)n2)cc1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NFKB1 P19838 3/20 0.41
NFKB2 Q00653 3/20 0.41
RELA Q04206 3/20 0.41
MAPT P10636 2/20 0.41
TP53 P04637 2/20 0.41
PPARA Q07869 4/20 0.40
PPARG P37231 3/20 0.40
PPARD Q03181 2/20 0.40
LMNA P02545 3/20 0.40
TSHR P16473 3/20 0.40
MAPK1 P28482 3/20 0.40
ALOX15 P16050 2/20 0.40
ALDH1A1 P00352 2/20 0.39
HTT P42858 2/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4575329 0.92 PPARA (0.40) NPC1RAB9AMAPTTP53PPARA
SCHEMBL4598247 0.91 PPARA (0.43) MAPTPPARAPPARGPPARDLMNA
SCHEMBL4574848 0.90 LMNA (0.43) SMN1; SMN2PPARAPPARGPPARDLMNA
SCHEMBL4576160 0.89 PPARA (0.44) PPARAPPARGPPARDLMNATSHR
SCHEMBL4575126 0.88 TUBB4A (0.41) NPC1RAB9ASMN1; SMN2MAPTPPARA
SCHEMBL4575545 0.88 NPC1 (0.40) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL4575831 0.87 PPARA (0.43) SMN1; SMN2PPARAPPARGPPARDLMNA
SCHEMBL4576216 0.87 MEN1 (0.41) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL4575317 0.87 PPARA (0.39) PPARAPPARGPPARDLMNATSHR
SCHEMBL4575172 0.87 ALDH1A1 (0.44) NPC1RAB9ASMN1; SMN2MAPTPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-20050137212-A1 Hppars activators SMITHKLINE BEECHAM CORPORATION 2005-06-23 US disclosed
EP-1480957-A1 HPPARS ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-01 EP disclosed
WO-2003074495-A1 HPPARS ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137212-A1 Hppars activators PPARG, PPARA, PPARD NPC1 400/4885RAB9A 1733/4885SMN1; SMN2 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.